Send to

Choose Destination
JCI Insight. 2018 Sep 20;3(18). pii: 120493. doi: 10.1172/jci.insight.120493. eCollection 2018 Sep 20.

A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.

Author information

Division of Genetics and Genomics at Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Pediatrics, Division of Neurology at the University of Alabama at Birmingham and Children's of Alabama, Birmingham, Alabama, USA.
UAB Center for Exercise Medicine at the University of Alabama at Birmingham, Birmingham, Alabama, USA.
Southern Research, Department of Chemistry, Birmingham, Alabama, USA.
Department of Pathophysiology, Tokyo Medical University, Tokyo, Japan.
Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
The Manton Center for Orphan Disease Research at Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Genetics at the University of Alabama at Birmingham, Birmingham, Alabama, USA.


Zebrafish are a powerful tool for studying muscle function owing to their high numbers of offspring, low maintenance costs, evolutionarily conserved muscle functions, and the ability to rapidly take up small molecular compounds during early larval stages. Fukutin-related protein (FKRP) is a putative protein glycosyltransferase that functions in the Golgi apparatus to modify sugar chain molecules of newly translated proteins. Patients with mutations in the FKRP gene can have a wide spectrum of clinical symptoms with varying muscle, eye, and brain pathologies depending on the location of the mutation in the FKRP protein. Patients with a common L276I FKRP mutation have mild adult-onset muscle degeneration known as limb-girdle muscular dystrophy 2I (LGMD2I), whereas patients with more C-terminal pathogenic mutations develop the severe Walker-Warburg syndrome (WWS)/muscle-eye-brain (MEB) disease. We generated fkrp-mutant zebrafish that phenocopy WWS/MEB pathologies including severe muscle breakdowns, head malformations, and early lethality. We have also generated a milder LGMD2I-model zebrafish via overexpression of a heat shock-inducible human FKRP (L276I) transgene that shows milder muscle pathology. Screening of an FDA-approved drug compound library in the LGMD2I zebrafish revealed a strong propensity towards steroids, antibacterials, and calcium regulators in ameliorating FKRP-dependent pathologies. Together, these studies demonstrate the utility of the zebrafish to both study human-specific FKRP mutations and perform compound library screenings for corrective drug compounds to treat muscular dystrophies.


Drug screens; Muscle Biology

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center